🇺🇸 FDA
Patent

US 7166704

Antibodies immunologically specific for PD2, a protein that is amplified and overexpressed in pancreatic cancer

granted A61KA61K38/00

Quick answer

US patent 7166704 (Antibodies immunologically specific for PD2, a protein that is amplified and overexpressed in pancreatic cancer) held by BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA expires Mon Jan 18 2027 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA
Grant date
Tue Jan 23 2007 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 18 2027 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
9
CPC classes
A61K, A61K38/00